| . | Total (N = 270) . | Moderate (n = 203) . | Severe or Critical (n = 67) . |
|---|---|---|---|
| Characteristic | |||
| Age, years | 62 (50–69) | 61 (50–68) | 66 (54–73) |
| Sex | |||
| Male | 139 (51.5%) | 86 (42.4%) | 45 (67.2%) |
| Female | 131 (48.5%) | 117 (57.6%) | 22 (32.8%) |
| Time from onset of symptoms to hospital admission, days | 10 (7–15) | 10 (7–15) | 7 (6–10) |
| Time from hospital admission to outcome, days | 9 (6–13) | 8 (7–13) | 10 (5–18) |
| Smoking history, yes | 14 (5.2%) | 7 (3.4%) | 7 (10.4%) |
| Drinking history, yes | 14 (5.2%) | 6 (3%) | 8 (11.9%) |
| Respiratory rate, breaths per minute | 20 (20–22) | 20 (19–22) | 22 (20–25) |
| ≥24 breaths per minute | 37 (13.7%) | 16 (7.9%) | 21 (31.3%) |
| Distribution of patchy shadows or ground-glass opacity | |||
| Unilateral | 22 (8.1%) | 16 (7.9%) | 6 (9%) |
| Bilateral | 248 (91.9%) | 187 (92.1%) | 61 (91%) |
| Any comorbidity | 139 (51.5%) | 99 (48.8%) | 40 (59.7%) |
| Hypertension | 81 (30%) | 59 (29.1%) | 22 (32.8%) |
| Diabetes | 35 (13.0%) | 27 (13.3%) | 8 (11.9%) |
| Other heart disease | 11 (4.1%) | 5 (2.5%) | 6 (9.0%) |
| Chronic obstructive pulmonary disease | 10 (3.7%) | 7 (3.4%) | 3 (4.5%) |
| Malignancy | 9 (3.3%) | 3 (1.5%) | 6 (9.0%) |
| Chronic kidney disease | 8 (3.0%) | 4 (2.0%) | 4 (6.0%) |
| Cerebral infarction | 2 (0.7%) | 1 (0.5%) | 1 (1.5%) |
| Other comorbidities | 37 (13.7%) | 28 (13.8%) | 9 (13.4%) |
| Signs and symptoms | |||
| Fever | 202 (74.8%) | 150 (73.9%) | 52 (77.6%) |
| Cough | 181 (67%) | 132 (65%) | 49 (73.1%) |
| Sputum | 63 (23.3%) | 43 (21.2%) | 20 (29.9%) |
| Dyspnea | 45 (16.7%) | 19 (9.4%) | 26 (38.8%) |
| Fatigue | 116 (43%) | 84 (41.4%) | 32 (47.8%) |
| Chest tightness | 74 (27.4%) | 46 (22.7%) | 28 (41.8%) |
| Nausea | 21 (7.8%) | 13 (6.4%) | 8 (11.9%) |
| Dizziness | 13 (4.8%) | 7 (3.4%) | 6 (9%) |
| Headache | 13 (4.8%) | 8 (3.9%) | 5 (7.5%) |
| Panting | 31 (11.5%) | 20 (9.9%) | 11 (16.4%) |
| Pantalgia | 11 (4.1%) | 7 (3.4%) | 4 (6%) |
| Diarrhea | 42 (15.6%) | 33 (16.3%) | 9 (13.4%) |
| Nasal congestion | 1 (0.4%) | 1 (0.5%) | 0 (0%) |
| Vomiting | 8 (3%) | 3 (1.5%) | 5 (7.5%) |
| Myalgia | 4 (1.5%) | 3 (1.5%) | 1 (1.5%) |
| Arthralgia | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Polypnea | 46 (17%) | 34 (16.7%) | 12 (17.9%) |
| Sore throat | 19 (7%) | 14 (6.9%) | 5 (7.5%) |
| Rhinorrhea | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Hemoptysis | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Cold intolerance | 5 (1.9%) | 4 (2%) | 1 (1.5%) |
| Syncope | 3 (1.1%) | 0 (0%) | 3 (4.5%) |
| Cardiopalmus | 7 (2.6%) | 4 (2%) | 3 (4.5%) |
| Chest pain | 12 (4.4%) | 8 (3.9%) | 4 (6%) |
| Abdominal pain | 4 (1.5%) | 4 (2%) | 0 (0%) |
| Antiviral or antiinflammatory drugs | |||
| Oseltamivir | 85 (31.5%) | 64 (31.5%) | 21 (31.3%) |
| Lopinavir | 134 (49.6%) | 94 (46.3%) | 40 (59.7%) |
| Arbidol | 89 (33.0%) | 61 (30.0%) | 28 (41.8%) |
| Lianhua Qingwen | 173 (64.1%) | 137 (67.5%) | 36 (53.7%) |
| Traditional Chinese medicine | 39 (14.4%) | 31 (15.3%) | 8 (11.9%) |
| Ribavirin | 11 (4.1%) | 7 (3.4%) | 4 (6.0%) |
| Methylprednisolone | 36 (13.3%) | 11 (5.4%) | 25 (37.3%) |
| Diammonium glycyrrhizinate enteric-coated capsules | 13 (4.8%) | 10 (4.9%) | 3 (4.5%) |
| Remdesivir | 4 (1.5%) | 2 (1.0%) | 2 (3.0%) |
| . | Total (N = 270) . | Moderate (n = 203) . | Severe or Critical (n = 67) . |
|---|---|---|---|
| Characteristic | |||
| Age, years | 62 (50–69) | 61 (50–68) | 66 (54–73) |
| Sex | |||
| Male | 139 (51.5%) | 86 (42.4%) | 45 (67.2%) |
| Female | 131 (48.5%) | 117 (57.6%) | 22 (32.8%) |
| Time from onset of symptoms to hospital admission, days | 10 (7–15) | 10 (7–15) | 7 (6–10) |
| Time from hospital admission to outcome, days | 9 (6–13) | 8 (7–13) | 10 (5–18) |
| Smoking history, yes | 14 (5.2%) | 7 (3.4%) | 7 (10.4%) |
| Drinking history, yes | 14 (5.2%) | 6 (3%) | 8 (11.9%) |
| Respiratory rate, breaths per minute | 20 (20–22) | 20 (19–22) | 22 (20–25) |
| ≥24 breaths per minute | 37 (13.7%) | 16 (7.9%) | 21 (31.3%) |
| Distribution of patchy shadows or ground-glass opacity | |||
| Unilateral | 22 (8.1%) | 16 (7.9%) | 6 (9%) |
| Bilateral | 248 (91.9%) | 187 (92.1%) | 61 (91%) |
| Any comorbidity | 139 (51.5%) | 99 (48.8%) | 40 (59.7%) |
| Hypertension | 81 (30%) | 59 (29.1%) | 22 (32.8%) |
| Diabetes | 35 (13.0%) | 27 (13.3%) | 8 (11.9%) |
| Other heart disease | 11 (4.1%) | 5 (2.5%) | 6 (9.0%) |
| Chronic obstructive pulmonary disease | 10 (3.7%) | 7 (3.4%) | 3 (4.5%) |
| Malignancy | 9 (3.3%) | 3 (1.5%) | 6 (9.0%) |
| Chronic kidney disease | 8 (3.0%) | 4 (2.0%) | 4 (6.0%) |
| Cerebral infarction | 2 (0.7%) | 1 (0.5%) | 1 (1.5%) |
| Other comorbidities | 37 (13.7%) | 28 (13.8%) | 9 (13.4%) |
| Signs and symptoms | |||
| Fever | 202 (74.8%) | 150 (73.9%) | 52 (77.6%) |
| Cough | 181 (67%) | 132 (65%) | 49 (73.1%) |
| Sputum | 63 (23.3%) | 43 (21.2%) | 20 (29.9%) |
| Dyspnea | 45 (16.7%) | 19 (9.4%) | 26 (38.8%) |
| Fatigue | 116 (43%) | 84 (41.4%) | 32 (47.8%) |
| Chest tightness | 74 (27.4%) | 46 (22.7%) | 28 (41.8%) |
| Nausea | 21 (7.8%) | 13 (6.4%) | 8 (11.9%) |
| Dizziness | 13 (4.8%) | 7 (3.4%) | 6 (9%) |
| Headache | 13 (4.8%) | 8 (3.9%) | 5 (7.5%) |
| Panting | 31 (11.5%) | 20 (9.9%) | 11 (16.4%) |
| Pantalgia | 11 (4.1%) | 7 (3.4%) | 4 (6%) |
| Diarrhea | 42 (15.6%) | 33 (16.3%) | 9 (13.4%) |
| Nasal congestion | 1 (0.4%) | 1 (0.5%) | 0 (0%) |
| Vomiting | 8 (3%) | 3 (1.5%) | 5 (7.5%) |
| Myalgia | 4 (1.5%) | 3 (1.5%) | 1 (1.5%) |
| Arthralgia | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Polypnea | 46 (17%) | 34 (16.7%) | 12 (17.9%) |
| Sore throat | 19 (7%) | 14 (6.9%) | 5 (7.5%) |
| Rhinorrhea | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Hemoptysis | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Cold intolerance | 5 (1.9%) | 4 (2%) | 1 (1.5%) |
| Syncope | 3 (1.1%) | 0 (0%) | 3 (4.5%) |
| Cardiopalmus | 7 (2.6%) | 4 (2%) | 3 (4.5%) |
| Chest pain | 12 (4.4%) | 8 (3.9%) | 4 (6%) |
| Abdominal pain | 4 (1.5%) | 4 (2%) | 0 (0%) |
| Antiviral or antiinflammatory drugs | |||
| Oseltamivir | 85 (31.5%) | 64 (31.5%) | 21 (31.3%) |
| Lopinavir | 134 (49.6%) | 94 (46.3%) | 40 (59.7%) |
| Arbidol | 89 (33.0%) | 61 (30.0%) | 28 (41.8%) |
| Lianhua Qingwen | 173 (64.1%) | 137 (67.5%) | 36 (53.7%) |
| Traditional Chinese medicine | 39 (14.4%) | 31 (15.3%) | 8 (11.9%) |
| Ribavirin | 11 (4.1%) | 7 (3.4%) | 4 (6.0%) |
| Methylprednisolone | 36 (13.3%) | 11 (5.4%) | 25 (37.3%) |
| Diammonium glycyrrhizinate enteric-coated capsules | 13 (4.8%) | 10 (4.9%) | 3 (4.5%) |
| Remdesivir | 4 (1.5%) | 2 (1.0%) | 2 (3.0%) |
Data are presented as median (interquartile range), n (n/N%), where N is the total number of confirmed patients.
| . | Total (N = 270) . | Moderate (n = 203) . | Severe or Critical (n = 67) . |
|---|---|---|---|
| Characteristic | |||
| Age, years | 62 (50–69) | 61 (50–68) | 66 (54–73) |
| Sex | |||
| Male | 139 (51.5%) | 86 (42.4%) | 45 (67.2%) |
| Female | 131 (48.5%) | 117 (57.6%) | 22 (32.8%) |
| Time from onset of symptoms to hospital admission, days | 10 (7–15) | 10 (7–15) | 7 (6–10) |
| Time from hospital admission to outcome, days | 9 (6–13) | 8 (7–13) | 10 (5–18) |
| Smoking history, yes | 14 (5.2%) | 7 (3.4%) | 7 (10.4%) |
| Drinking history, yes | 14 (5.2%) | 6 (3%) | 8 (11.9%) |
| Respiratory rate, breaths per minute | 20 (20–22) | 20 (19–22) | 22 (20–25) |
| ≥24 breaths per minute | 37 (13.7%) | 16 (7.9%) | 21 (31.3%) |
| Distribution of patchy shadows or ground-glass opacity | |||
| Unilateral | 22 (8.1%) | 16 (7.9%) | 6 (9%) |
| Bilateral | 248 (91.9%) | 187 (92.1%) | 61 (91%) |
| Any comorbidity | 139 (51.5%) | 99 (48.8%) | 40 (59.7%) |
| Hypertension | 81 (30%) | 59 (29.1%) | 22 (32.8%) |
| Diabetes | 35 (13.0%) | 27 (13.3%) | 8 (11.9%) |
| Other heart disease | 11 (4.1%) | 5 (2.5%) | 6 (9.0%) |
| Chronic obstructive pulmonary disease | 10 (3.7%) | 7 (3.4%) | 3 (4.5%) |
| Malignancy | 9 (3.3%) | 3 (1.5%) | 6 (9.0%) |
| Chronic kidney disease | 8 (3.0%) | 4 (2.0%) | 4 (6.0%) |
| Cerebral infarction | 2 (0.7%) | 1 (0.5%) | 1 (1.5%) |
| Other comorbidities | 37 (13.7%) | 28 (13.8%) | 9 (13.4%) |
| Signs and symptoms | |||
| Fever | 202 (74.8%) | 150 (73.9%) | 52 (77.6%) |
| Cough | 181 (67%) | 132 (65%) | 49 (73.1%) |
| Sputum | 63 (23.3%) | 43 (21.2%) | 20 (29.9%) |
| Dyspnea | 45 (16.7%) | 19 (9.4%) | 26 (38.8%) |
| Fatigue | 116 (43%) | 84 (41.4%) | 32 (47.8%) |
| Chest tightness | 74 (27.4%) | 46 (22.7%) | 28 (41.8%) |
| Nausea | 21 (7.8%) | 13 (6.4%) | 8 (11.9%) |
| Dizziness | 13 (4.8%) | 7 (3.4%) | 6 (9%) |
| Headache | 13 (4.8%) | 8 (3.9%) | 5 (7.5%) |
| Panting | 31 (11.5%) | 20 (9.9%) | 11 (16.4%) |
| Pantalgia | 11 (4.1%) | 7 (3.4%) | 4 (6%) |
| Diarrhea | 42 (15.6%) | 33 (16.3%) | 9 (13.4%) |
| Nasal congestion | 1 (0.4%) | 1 (0.5%) | 0 (0%) |
| Vomiting | 8 (3%) | 3 (1.5%) | 5 (7.5%) |
| Myalgia | 4 (1.5%) | 3 (1.5%) | 1 (1.5%) |
| Arthralgia | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Polypnea | 46 (17%) | 34 (16.7%) | 12 (17.9%) |
| Sore throat | 19 (7%) | 14 (6.9%) | 5 (7.5%) |
| Rhinorrhea | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Hemoptysis | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Cold intolerance | 5 (1.9%) | 4 (2%) | 1 (1.5%) |
| Syncope | 3 (1.1%) | 0 (0%) | 3 (4.5%) |
| Cardiopalmus | 7 (2.6%) | 4 (2%) | 3 (4.5%) |
| Chest pain | 12 (4.4%) | 8 (3.9%) | 4 (6%) |
| Abdominal pain | 4 (1.5%) | 4 (2%) | 0 (0%) |
| Antiviral or antiinflammatory drugs | |||
| Oseltamivir | 85 (31.5%) | 64 (31.5%) | 21 (31.3%) |
| Lopinavir | 134 (49.6%) | 94 (46.3%) | 40 (59.7%) |
| Arbidol | 89 (33.0%) | 61 (30.0%) | 28 (41.8%) |
| Lianhua Qingwen | 173 (64.1%) | 137 (67.5%) | 36 (53.7%) |
| Traditional Chinese medicine | 39 (14.4%) | 31 (15.3%) | 8 (11.9%) |
| Ribavirin | 11 (4.1%) | 7 (3.4%) | 4 (6.0%) |
| Methylprednisolone | 36 (13.3%) | 11 (5.4%) | 25 (37.3%) |
| Diammonium glycyrrhizinate enteric-coated capsules | 13 (4.8%) | 10 (4.9%) | 3 (4.5%) |
| Remdesivir | 4 (1.5%) | 2 (1.0%) | 2 (3.0%) |
| . | Total (N = 270) . | Moderate (n = 203) . | Severe or Critical (n = 67) . |
|---|---|---|---|
| Characteristic | |||
| Age, years | 62 (50–69) | 61 (50–68) | 66 (54–73) |
| Sex | |||
| Male | 139 (51.5%) | 86 (42.4%) | 45 (67.2%) |
| Female | 131 (48.5%) | 117 (57.6%) | 22 (32.8%) |
| Time from onset of symptoms to hospital admission, days | 10 (7–15) | 10 (7–15) | 7 (6–10) |
| Time from hospital admission to outcome, days | 9 (6–13) | 8 (7–13) | 10 (5–18) |
| Smoking history, yes | 14 (5.2%) | 7 (3.4%) | 7 (10.4%) |
| Drinking history, yes | 14 (5.2%) | 6 (3%) | 8 (11.9%) |
| Respiratory rate, breaths per minute | 20 (20–22) | 20 (19–22) | 22 (20–25) |
| ≥24 breaths per minute | 37 (13.7%) | 16 (7.9%) | 21 (31.3%) |
| Distribution of patchy shadows or ground-glass opacity | |||
| Unilateral | 22 (8.1%) | 16 (7.9%) | 6 (9%) |
| Bilateral | 248 (91.9%) | 187 (92.1%) | 61 (91%) |
| Any comorbidity | 139 (51.5%) | 99 (48.8%) | 40 (59.7%) |
| Hypertension | 81 (30%) | 59 (29.1%) | 22 (32.8%) |
| Diabetes | 35 (13.0%) | 27 (13.3%) | 8 (11.9%) |
| Other heart disease | 11 (4.1%) | 5 (2.5%) | 6 (9.0%) |
| Chronic obstructive pulmonary disease | 10 (3.7%) | 7 (3.4%) | 3 (4.5%) |
| Malignancy | 9 (3.3%) | 3 (1.5%) | 6 (9.0%) |
| Chronic kidney disease | 8 (3.0%) | 4 (2.0%) | 4 (6.0%) |
| Cerebral infarction | 2 (0.7%) | 1 (0.5%) | 1 (1.5%) |
| Other comorbidities | 37 (13.7%) | 28 (13.8%) | 9 (13.4%) |
| Signs and symptoms | |||
| Fever | 202 (74.8%) | 150 (73.9%) | 52 (77.6%) |
| Cough | 181 (67%) | 132 (65%) | 49 (73.1%) |
| Sputum | 63 (23.3%) | 43 (21.2%) | 20 (29.9%) |
| Dyspnea | 45 (16.7%) | 19 (9.4%) | 26 (38.8%) |
| Fatigue | 116 (43%) | 84 (41.4%) | 32 (47.8%) |
| Chest tightness | 74 (27.4%) | 46 (22.7%) | 28 (41.8%) |
| Nausea | 21 (7.8%) | 13 (6.4%) | 8 (11.9%) |
| Dizziness | 13 (4.8%) | 7 (3.4%) | 6 (9%) |
| Headache | 13 (4.8%) | 8 (3.9%) | 5 (7.5%) |
| Panting | 31 (11.5%) | 20 (9.9%) | 11 (16.4%) |
| Pantalgia | 11 (4.1%) | 7 (3.4%) | 4 (6%) |
| Diarrhea | 42 (15.6%) | 33 (16.3%) | 9 (13.4%) |
| Nasal congestion | 1 (0.4%) | 1 (0.5%) | 0 (0%) |
| Vomiting | 8 (3%) | 3 (1.5%) | 5 (7.5%) |
| Myalgia | 4 (1.5%) | 3 (1.5%) | 1 (1.5%) |
| Arthralgia | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Polypnea | 46 (17%) | 34 (16.7%) | 12 (17.9%) |
| Sore throat | 19 (7%) | 14 (6.9%) | 5 (7.5%) |
| Rhinorrhea | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Hemoptysis | 2 (0.7%) | 2 (1%) | 0 (0%) |
| Cold intolerance | 5 (1.9%) | 4 (2%) | 1 (1.5%) |
| Syncope | 3 (1.1%) | 0 (0%) | 3 (4.5%) |
| Cardiopalmus | 7 (2.6%) | 4 (2%) | 3 (4.5%) |
| Chest pain | 12 (4.4%) | 8 (3.9%) | 4 (6%) |
| Abdominal pain | 4 (1.5%) | 4 (2%) | 0 (0%) |
| Antiviral or antiinflammatory drugs | |||
| Oseltamivir | 85 (31.5%) | 64 (31.5%) | 21 (31.3%) |
| Lopinavir | 134 (49.6%) | 94 (46.3%) | 40 (59.7%) |
| Arbidol | 89 (33.0%) | 61 (30.0%) | 28 (41.8%) |
| Lianhua Qingwen | 173 (64.1%) | 137 (67.5%) | 36 (53.7%) |
| Traditional Chinese medicine | 39 (14.4%) | 31 (15.3%) | 8 (11.9%) |
| Ribavirin | 11 (4.1%) | 7 (3.4%) | 4 (6.0%) |
| Methylprednisolone | 36 (13.3%) | 11 (5.4%) | 25 (37.3%) |
| Diammonium glycyrrhizinate enteric-coated capsules | 13 (4.8%) | 10 (4.9%) | 3 (4.5%) |
| Remdesivir | 4 (1.5%) | 2 (1.0%) | 2 (3.0%) |
Data are presented as median (interquartile range), n (n/N%), where N is the total number of confirmed patients.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
